Influenza Vaccine Market

Influenza Vaccine Market Overview

The influenza vaccine market size is projected to grow from USD 8.27 billion in 2025 to USD 17.41 billion by 2035, representing a CAGR of 7.72% during the forecast period till 2035.

To learn more about this report, request a free sample copy

The new research study consists of influenza vaccine market and trends analysis, detailed market forecast analysis, and provides actionable strategic recommendations.

Influenza, also known as flu, an acute respiratory infection spread by the influenza virus is a common viral infectious disease. According to WHO’s report, each year, seasonal influenza affects around a billion people and 3-5 million cases experience severe illness. Nearly 650,000 deaths are caused by respiratory conditions. It is important to note that in developing nations, 99% of influenza-related lower respiratory tract infection deaths occur in children under five. As an effect, with this growing number of influenza cases, the global influenza vaccine market is evolving exponentially.

The influenza vaccine is a flu shot that protects against infection by influenza viruses. Inactivated vaccines and live attenuated vaccines are the most popular vaccines approved by the Centers for Disease Control and Prevention and the World Health Organization which are widely used for all age groups of patients. By understanding the scenarios, government and healthcare organizations are running extensive vaccination campaigns to promote immunization and strengthen disease surveillance systems as it plays a critical role in detecting and preventing the spread of infectious diseases.

Pharmaceutical innovations are at the forefront of this shift, with new formulations designed to enhance vaccine efficacy against various influenza virus types. The latest vaccine efficacy studies provide compelling evidence of their effectiveness, underscoring the importance of widespread immunization in mitigating flu outbreaks.

Moreover, governments are providing funding and subsidies for the innovation of next-generation vaccines, procurement, and distribution. For instance, in January 2025, The US government allocated an additional $590 million to Moderna to expedite the development of its mRNA-based H5N1 avian influenza vaccine. This investment shows a commitment to leveraging mRNA technology for the rapid development of vaccines in response to a potential pandemic. Considering these factors, the market for influenza vaccine is expected to sprout out exceptionally driven by key driving factors and industry trends. However, increased production timelines and skepticism about vaccine efficiency on virus mutation are some barriers that need to be addressed to reach the market to its full potential growth during this forecast period.

Influenza Vaccine Market Share Insights

The influenza vaccine market report presents an in-depth analysis of the various companies that are involved in offering influenza vaccines, across different segments, as defined in the table below:

Influenza Vaccine Market: Report Attributes / Market Segmentations

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Current Market Size	$ 8.27 Billion
Market Size Value by 2035	$ 17.41 Billion
CAGR (Till 2035)	7.72%
Type of Vaccine	Inactivated Vaccines Live Attenuated Vaccines
Type of Valency	Quadrivalent Vaccines Trivalent Vaccines
Age Group	Adult Geriatric Pediatric
Type of Technology	Cell-Based Production Egg-Based Production
Distribution Channel	Government Supplies Hospital Pharmacy Online Pharmacy Retail Pharmacy
Geographical Regions	North America US Canada Mexico Other North American countries Europe Austria Belgium Denmark France Germany Ireland Italy Netherlands Norway Russia Spain Sweden Switzerland UK Other European countries Asia China India Japan Singapore South Korea Other Asian countries Latin America Brazil Chile Colombia Venezuela Other Latin American countries Middle East and North Africa Egypt Iran Iraq Israel Kuwait Saudi Arabia UAE Other MENA countries Rest of the World Australia New Zealand Other countries
Leading Market Players	AstraZeneca Boehringer Ingelheim International Bristol-Myers Squibb F. Hoffman-La Roche GlaxoSmithKline Pic GSK Merck Mylan NV Novartis OSIVAX Pfizer Sanofi SHINOVAC SHIONOGI Viatris
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Competitive Landscape Company Competitive Analysis Patent Analysis Funding Analysis Recent Developments Market Forecast and Opportunity Analysis

Influenza Vaccine Market Segmentation

Market Share by Type of Vaccine

This segmentation highlights the variety of vaccines including inactivated vaccines and live attenuated vaccines. As per influenza vaccine market research, the inactivated vaccine segment has been driving the market growth with the maximum (~66%) of the market share and will likely hold this position till the forecast period. This can be attributed to the broad applicability and safety profile of the vaccine. Inactivated vaccines contain killed influenza viruses, which cannot cause infection but still stimulate an immune response. Consequently, these are approved for use in all age groups including high-risk populations, and are commonly recommended by CDC and WHO.

Besides this, the live attenuated vaccine segment gaining traction in the industry and is expected to expand at a higher (9.65%) CAGR in the forthcoming years. Live attenuated vaccines contain weakened life influenza viruses that can replicate in the nasal mucosa but do not cause illness. They are generally administered as a nasal spray. Therefore, owing to its variable efficacy, the segment will likely continue to grow.

Market Share by Type of Valency

The market for influenza vaccines features different types of valency including quadrivalent vaccines and trivalent vaccines. According to our influenza vaccine market analysis, the quadrivalent vaccines lead the segment and are estimated to occupy the highest (~63%) of the market share in terms of revenue by 2035. Quadrivalent vaccines offer protection against both lineage of influenza A and B which trivalent vaccines do not cover. This reduces the risk of mismatches between the vaccine and circulating strains, hence, widely being produced and boosting the quadrivalent influenza vaccine market growth. For instance, in March 2024, an India-based company, Cadila Pharmaceuticals launched a new influenza vaccine called Cadiflu Tetra, a quadrivalent influenza vaccine approved by the Drug Controller General of India. This vaccine targets four strains of influenza virus type A and B and offers better protection against the seasonal flu.

Furthermore, the trivalent vaccines protect against three influenza strains two influenza A strains (H1N1 and H3N2) and one influenza B strain. With a growing preference for quadrivalent over trivalent, the trivalent vaccine segment is expected to rise at a moderate (7.81%) growth rate in the upcoming decade.

Market Share by Age Group

Based on the age group, the adult segment is projected to drive the market growth with (~43%) of the current market share and will lead the segment by 2035. The high vaccination program for immunization and increasing awareness of the importance of influenza vaccination among healthy adults to prevent transmission to high-risk groups are the key driving factors of the segment’s growth.

Furthermore, the pediatric segment is poised to grow at a notable CAGR of (10.14%) due to being the critical demographic for influenza vaccination. Young children particularly, those under 5 years are at higher risk of severe influenza complications including pneumonia, thus, accelerating the market scope.

Market Share by Type of Technology

This segmentation of the global influenza vaccine market is fragmented into multiple types of technology such as cell-based production and egg-based production. According to our influenza vaccine market report, egg-based production is the dominating technology and is expected to hold (~65%) of the market share by 2035. This dominance can be attributed to the widespread use of the technology and being a traditional method of vaccine production. Also, this is considered a well-understood and proven technology and is cost-effective for large-scale production.

Meanwhile, the cell-based production technology segment is gaining traction in the industry and is likely to witness a (10.5%) growth rate during this forecast period. This technology uses mammalian cell cultures to grow the influenza virus which eliminates the need for eggs. The key advantages such as faster production timelines are fostering the segment’s growth.

Market Share by Type of Distribution Channel

On the basis of the type of distribution channel, hospital pharmacy has been dominating the segment and is anticipated to retain its position by capturing (~39%) of the market share by 2035. Hospitals and clinics are the primary vaccine distribution systems, particularly, for high-risk groups such as the elderly and children with chronic health conditions. As these vaccines are often administered directly by healthcare providers in these settings, thereby, soaring the growth of the influenza vaccine industry.

Moreover, retail pharmacies are emerging rapidly and are likely to rise at the fastest (11.58%) growth rate in the upcoming decade owing the convenience and wider accessibility. Retail pharmacies offer easier access to vaccines for the general public, thereby, advancing the market outlook.

Market Share by Geographical Regions

This segment highlights the distribution of the influenza vaccine market across various geographical regions, such as North America, Europe, Asia, Latin America, the Middle East and North Africa, and the rest of the world. As per regional influenza vaccine market insights, North America is poised to capture the largest market (~47%) of the current market share and will dominate the industry till 2035. Additionally, Asia exhibits strong growth in the market and is estimated to rise at the fastest CAGR of (11.87%) during this projection timeframe. The perpetuated growth of the population in Asia generates substantial demand for vaccines. This is due to the fact that rapid urbanization in emerging nations in the region leads to higher density populations which facilitate the spread of infectious diseases similar to influenza, widening the influenza vaccine market outlook.

Apart from this, increasing healthcare expenditure, a rise in awareness of the importance of vaccination and risks associated with influenza multiply the growth of the industry in the region. As a result, governments and healthcare organizations in Asia are investing in vaccination programs to improve public health outcomes. For instance, in August 2024, Apollo Clini launched a nationwide vaccination campaign for seasonal flu prevention similar to monsoon illness. The organization provided vaccinations & treatment for several monsoon related diseases and illnesses across all 102 clinics.

Influenza Vaccine Market Key Insights

The “Influenza Vaccine Market, Till-2035: Industry Trends and Global Forecasts” report features an extensive study of the current market landscape, market size and future opportunities within the influenza vaccine market, during the given forecast period. The market report highlights the efforts of several stakeholders involved in this rapidly emerging segment of the service providers industry. Key takeaways of the influenza vaccine market report are briefly discussed below.

Key Drivers of the Influenza Vaccine Market

The market has been evolving rapidly and is likely to continue to expand driven by the increasing prevalence of influenza around the world. Seasonal influenza outbreaks create a consistent demand for vaccines and create the potential for an influenza pandemic similar to H1N1 pandemic in 2009 which has heightened the need for effective vaccines. Therefore, vaccine manufacturing companies are continuing to driving the vaccine efficacy studies, inflating the market development. Along with this, public health initiatives and government support for pandemic preparedness is another major key driver in elevating the influenza vaccine market growth.

Government and public health organizations run widespread vaccination awareness campaigns, make global health policies, and flu season management program to promote immunization, advancing the market expansion. Furthermore, the development of next-generation vaccines such as cell-based and recombinant vaccines as well as mRNA technology has spurred interest in applying the technology to influenza vaccines and is anticipated to support the growth of the industry.

Influenza Vaccine Market Competitive Landscape

Presently several established global pharmaceutical companies, biotechnology firms, and a growing number of biotech startups are reshaping the competitive landscape of the seasonal influenza vaccine market. Prominent key players including Sanofi, GlaxoSmithKline, Seqirus, AstraZeneca, Pfizer, and many other influenza vaccine manufacturing companies drive market growth with their myriads of influenza vaccines, innovation, and R&D, strategies partnerships, and collaboration. Coupled with this, they are emphasizing regulatory approvals and global expansion which reinforce their market position. These brands are constantly striving to boost their competitive edge by innovating vaccine development technologies and improving vaccine efficacy further which help them secure significant market share.

Market Challenges in Influenza Vaccine Market

The production of influenza vaccines is a long-term process that entails growing the virus in eggs or cell cultures which can take several months. The complexity in the development of vaccine research and regulatory compliance are the leading cause in expanding the timeline of vaccination development. This can make it difficult to respond quickly to emerging strains. Along with this, virus variability and vaccine efficacy which can vary from year to year, depending on how well vaccine strains match the circulating virus can lower the effectiveness of the vaccines. Therefore, increased production timelines and lower vaccine efficacy are some considerable challenges that need to be addressed to maintain the current growth of the market throughout this projection period.

Regional Analysis: North America is Expected to Dominate the Market with the Largest Influenza Vaccine Market Share

In terms of revenue generation North America is projected to dominate the industry with (~47%) share of the market driven by advanced healthcare infrastructure development. The US and Canada boast a robust developed healthcare system with widespread access to medical services including flu vaccination programs. They represent a higher public awareness about the importance of influenza vaccination supported by huge public health campaigns and recommendation from health authorities.

Key industry players and their strong market position aid in the growth of the market in the region. For instance, in July 2024, GSK shipped its trivalent influenza vaccines to US healthcare providers and pharmacies for the 2024-25 flu season. These are the WHO-recommended B/Yamagata strains from seasonal flu vaccines, and the recommended strains for egg-based trivalent vaccines are outlined. Besides this, strong government support for vaccination through funding, and robust R&D capabilities with high healthcare expenditure are further solidifying the market dominance in the global marketplace.

Leading Influenza Vaccine Manufacturers

Examples of key players involved in the market for influenza vaccine (which have also been captured in this market report, arranged in alphabetical order) include AstraZeneca (UK), Boehringer Ingelheim International (Germany), Bristol-Myers Squibb (US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Merck (US), Mylan NV (US), Novartis (Switzerland), OSIVAX (France), Pfizer (US), Sanofi (France), Sinovac (China), Shionogi (Japan), Viatris (US). This market report includes an easily searchable excel database of all the companies who have adopted the influenza vaccine market.

Recent Developments in Influenza Vaccine Market

• In February 2025, Zydus Lifescience introduced a vaccine for a new strain of influenza virus. This is the company’s first flu protection quadrivalent influenza virus vaccine based on WHO-recommended composition.
• In February 2025, Boehringer Ingelheim launched the latest VAXXITEK® HVT+IBD+H5 trivalent poultry vaccine which offers protection against Marek’s disease, Infectious Bursal Disease, and H5avian influenza.
• In September 2024, The FDA approved FluMist for self- caregiver-administration. This nasal spray vaccine prevents influenza (A and B strains) in individuals aged 2-49. This is the first influenza vaccine that does not require a necessary prescription by a healthcare provider.

Influenza Vaccine Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain, across different segments. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report influenza vaccine market, 2020-2024 (Historical Trends) and till-2035 (Forecasted Estimates).
• An outline of the systematic research methodology adopted to conduct the study on the influenza vaccine market providing insights on the various assumptions, methodologies, and quality control measures employed to ensure the accuracy and reliability of our findings.
• An overview of economic factors that impact the overall influenza vaccine market including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the insights captured during our research. It offers a high-level view on the current state of the influenza vaccine market their likely evolution in the mid-long term.
• A detailed assessment of the influenza vaccine market landscape, based on several relevant parameters, including year of experience, company size, location of headquarters, and ownership structure.
• Elaborate profiles of prominent players engaged in the influenza vaccine market, featuring information on their year of establishment, location of headquarters, company size, company mission, company footprint, management team, contact details, financial information, operating business segments, influenza vaccine market portfolio, moat analysis, recent developments, and an informed future outlook.
• A qualitative assessment of the various megatrends ongoing in the influenza vaccine industry, including growing advancements toward a universal flu vaccine and increasing government funding for mRNA-based flu vaccines.
• An analysis highlighting the key unmet needs across the influenza vaccine market, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, industry blogs and the views of key opinion leaders expressed on online platforms.
• An in-depth analysis of various patents that have been filed / granted related to influenza vaccine market and its components, based on various parameters, such as type of patent, patent publication year, patent age and leading players.
• A detailed analysis of recent developments in the influenza vaccine market domain, based on relevant parameters such as year of initiative, type of initiative (partnerships and collaborations, expansions, funding and product launches), geographical distribution and most active players (in terms of number of recent developments).
• Key winning strategies framework that helps in analyzing the level of competition within an industry, by tracing the key market activities including partnership, funding, expansion of leading players
• A qualitative analysis, highlighting the five competitive forces prevalent in the influenza vaccine market including threats for new entrants, bargaining power of suppliers, bargaining power of customers, threats of substitution and rivalry among existing competitors.
• A discussion on affiliated global Influenza Vaccine Market trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall influenza vaccine market.
• A value chain analysis featuring a discussion on various stakeholders involved in the development of the influenza vaccine market, from suppliers to end-users.
• A detailed estimate of the current market size and the future growth potential of the influenza vaccine market over the next decade. Based on multiple parameters we have provided an informed estimate on the market evolution during the forecast period 2025-2035. The report also features the likely distribution of the current and forecasted opportunity within the influenza vaccine market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current and future market across various types of vaccines such as inactivated vaccines and live attenuated vaccines.
• Detailed projections of the current and future market across various types of valency such as quadrivalent vaccines and trivalent vaccines.
• Detailed projections of the current and future market across various types of age groups such as adult, geriatric, and pediatric.
• Detailed projections of the current and future market across various types of technology such as cell-based production and egg-based production.
• Detailed projections of the current and future market across various types of distribution channels such as government supplies, hospitals, online pharmacies, and retail pharmacies.
• Detailed projections of the current and future influenza vaccine market across various geographical regions, such as North America (US, Canada, Mexico and other North American countries), Europe (Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Russia, Spain, Sweden, Switzerland, UK and other European countries), Asia (China, India, Japan, Singapore, South Korea and other Asian countries), Middle East and North Africa (Egypt, Iran, Iraq, Israel, Kuwait, Saudi Arabia, UAE and other MENA countries), Latin America (Brazil, Chile, Colombia, Venezuela and other Latin American countries) and rest of the world (Australia, New Zealand and other countries).

Customization Opportunities

At Roots Analysis, we genuinely care about your success and understand that your business requirements are unique. While our market research reports provide valuable insights, we recognize that they might not cover every aspect you need to make well-informed strategic decisions. To account for that, we offer 15% free report customization tailored to your specific needs. Whether you require additional quantitative analysis, qualitative insights, or any other information related to the influenza vaccine market, reach out us today at: support@rootsanalysis.com